Methods We obtained nasal AECs by brush sampling from children with severe atopic asthma (AA) and healthy controls (HC) (n=3–6). Cells were cultured in the presence/absence of the predicted drugs amitriptyline and prednisone and stimulated with lipopolysaccharide (LPS, 10 μg/mL, 0–24h), to mimic a bacterial infection. A20 and p65 mRNA and the release of pro-inflammatory cytokines from AEC cultures were determined.

Results AEC basal A20 was lower in AA compared to HC (p<0.05). LPS stimulation induced A20 in HC rapidly (peak at 1h LPS, p<0.05) and the elevated levels were maintained for up to 4 hours. In AA, LPS also caused an increase in A20 mRNA (lower than in HC) and found to be only elevated at 4h. NF-kb p65 significantly increased 1h after LPS stimulation in HC and 4h after LPS in AA cells (both p<0.05).

Amitriptyline (effective concentration 10 μM), increased A20 levels in both HC and AA epithelial cells. HC responded with a peak expression at 1h LPS (p<0.05), while in AA cells, we observed a steady increase in A20 for up to 24h LPS. Prednisone (10-3 μM) induced A20 with a peak expression at 4h in AA and HC, but the increase was significantly higher in HC epithelial cells.

The increase in A20 mRNA was paralleled by a significant decrease in p65 mRNA in amitriptyline and prednisone-treated cells and a decrease in IL-8 release.

Conclusion ScsMap predicted drugs that successfully induced the anti-inflammatory protein A20 in AECs, which resulted in a reduced inflammatory response to bacterial stimulation (LPS). Although the anti-inflammatory effect of prednisone is well established, we here add that this is mediated through the induction of A20. Furthermore, the application of amitriptyline as an anti-inflammatory medication may need further investigation. This proof of concept study using bioinformatics could be used to identify other drugs that could be repositioned as anti-inflammatory treatment in asthma.

OC43 IMPACT OF FLASH AND CONTINUOUS GLUCOSE MONITORING ON QUALITY OF LIFE AND DISEASE BURDEN IN CHILDREN WITH DIABETES MELLITUS AND THEIR FAMILIES

Elaine Murphy*, Eleanor Burke, Laura McCarron, Gillian O'Donnell, Eithin Carolan, Ciara McDonald, Nuala Murphy; Children’s University Hospital Temple Street, Dublin, Ireland

10.1136/archdischild-2019-epa.41

Introduction/Background Flash and continuous glucose monitoring technology has revolutionised the management of diabetes, particularly in paediatric populations. Recent government funding for flash glucose monitoring devices has enabled widespread usage in children and adolescents in the Republic of Ireland. We examined the impact of this novel technology on the lives of children with diabetes and their parents through the use of age modified questionnaires.

Design/Methods Qualitative research was carried out using anonymised ‘Quality of Life’ questionnaires. All children and adolescents and their families attending the diabetes service in Children’s University Hospital were eligible for the study and were invited to contribute at routine outpatient visit. Those using the technology were divided into three groups; preschool, primary school and secondary school. Together, children and their parents answered questions relating to ease of use, impact on schooling, independence, parent-child relationships and subjective burden of disease. Some sections were specific to the particular form of glucose monitoring [flash or continuous]; but those regarding impact on day-to-day management of diabetes and impact on quality of life were common to all. A separate questionnaire was used for patients not using either technology and explored the factors that influenced that decision.

Results Preliminary data (n=39) shows that patient and parent experiences with flash and continuous glucose monitoring technology have been overwhelmingly positive. 90% of children surveyed are using one of these devices. Across all age groups, 100% of those using the technology reported subjective improvement in glycaemic control. All adolescents reported increased confidence in their ability to manage diabetes and a greater degree of personal independence. Parents reported significant reduction in frequency of hypoglycaemic events and > 80% reported reduction in anxiety surrounding hypoglycaemia. >85% of both patients and parents found a significant reduction in the day-to-day burden of diabetes. Those not using glucose-monitoring devices listed parental concern regarding device accuracy and attachment of the device on the skin as the major deterring factors.

Conclusions This data demonstrates a positive impact of flash and continuous glucose monitoring on quality of life for children with diabetes mellitus. Government funding since 2018 has enabled equal access for all paediatric patients [over 4 years old] to this life-impacting technology which should now be offered to all children and adolescents, to include those with Type 2 Diabetes and other rarer sub-types, and those under 4 years old.